<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732039</url>
  </required_header>
  <id_info>
    <org_study_id>H-20049568</org_study_id>
    <nct_id>NCT04732039</nct_id>
  </id_info>
  <brief_title>Daily Life Activities in Patients Treated With Continuous-Flow Left Ventricular Assist Devices</brief_title>
  <acronym>Act-VAD</acronym>
  <official_title>Daily Life Activities in Patients Treated With Continuous-Flow Left Ventricular Assist Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of oxygen uptake during daily life activities in HF patients with and without&#xD;
      LVADs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with terminal HF the gold standard for treatment is heart transplantation, though&#xD;
      the Worldwide shortage of donor organs has led to increased use of implantable mechanical&#xD;
      circulatory support devices. The treatment with implantable pumps in the form of a Continuous&#xD;
      Flow Left Ventricular Assist Device (CF-LVAD, or simply LVAD) is extremely effective for a&#xD;
      selected patient groups leading to significant improvement in survival and quality of life.&#xD;
&#xD;
      The device is a battery-powered flow pump that carries the blood from the left ventricle to&#xD;
      the main artery, via a cannula, and thus relieves the failing left ventricle with up to 10&#xD;
      liters of blood per minute. An LVAD can be used both as lifelong support therapy (Destination&#xD;
      Therapy, DT) or until transplantation can take place (Bridge therapy).&#xD;
&#xD;
      As patients today live for more than 10 years with the device as DT, the focus has shifted&#xD;
      from mere survival to quality of life and physical ability.&#xD;
&#xD;
      In recent years, our research group showed that the pump speed and the patient's baseline&#xD;
      heart rhythm (sinus rhythm vs atrial fibrillation) and reduced ability to regulate the&#xD;
      intrinsic rhythm after implantation (chronotropic incompetence) are significant contributors&#xD;
      to the reduced exercise capacity seen in this patient group.&#xD;
&#xD;
      Until now, studies have elucidated the work capacity of this patient group using a 6-minute&#xD;
      walk test or bicycle test - none of these reflect how well the patient actually functions in&#xD;
      his everyday life.&#xD;
&#xD;
      In this study, we will describe oxygen uptake related to specific daily activities (ADL-VO2)&#xD;
      and compare these with the well-known maximum work capacity (percentage of expected oxygen&#xD;
      uptake / pVO2) in this patient group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized crossover study:&#xD;
Peak oxygen uptake vs VO2 measure during specific daily life activities in LVAD recipients&#xD;
Peak oxygen uptake vs VO2 measure during specific daily life activities in healthy controls</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VO2</measure>
    <time_frame>Stable LVAD recipients on average 2 years after the implantation</time_frame>
    <description>Oxygen uptake</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Left Ventricular Failure, Unspecified</condition>
  <arm_group>
    <arm_group_label>LVAD recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peak oxygen uptake vs VO2 measure during specific daily life activities in LVAD recipients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peak oxygen uptake vs VO2 measure during specific daily life activities in healthy controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measurement of peak oxygen uptake</intervention_name>
    <description>Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>LVAD recipients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        LVADs:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Implanted durable left ventricular assist device&#xD;
&#xD;
          -  Age&gt;18yrs&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No consent&#xD;
&#xD;
          -  Not able to complete VO2 test (physicians decision)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Finn Gustafsson, MD,PhD,DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kiran K Mirza, MD</last_name>
    <phone>+4535451442</phone>
    <email>KMIR0003@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
    <phone>004535459743</phone>
    <email>Finn.Gustafsson@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>DK</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Mirza, MD</last_name>
      <phone>+4535451442</phone>
      <email>KiranMirza@dadlnet.dk</email>
    </contact>
    <contact_backup>
      <last_name>Finn Gustafsson, MD,PhD,DMSc.</last_name>
      <phone>+4535459743</phone>
      <email>Finn.Gustafsson@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Finn Gustafsson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>left ventricular assist device</keyword>
  <keyword>oxygen uptake</keyword>
  <keyword>daily life activity</keyword>
  <keyword>quality of life</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

